Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 151 to 200 of 2490 results for term

  1. Long-term outcomes of bariatric surgery on people with type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in people with type 2 diabetes compared with optimal medical treatment?

    CG189/04 Question Long-term outcomes of bariatric surgery on people with type 2 diabetes: What is the long-term effect of...

  2. Long-term risk of renal scarring and impaired renal function: A well designed cohort study investigating long-term outcomes including renal scarring and renal function of children who have had UTI should be conducted in the UK.

    Question Long-term risk of renal scarring and impaired renal function: A well designed cohort study investigating...

  3. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

    Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.

  4. Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

    Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.

  5. Preterm labour and birth (NG25)

    This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

  6. Joint replacement (primary): hip, knee and shoulder (NG157)

    This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.

  7. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK? Any explanatory...

  8. Older people's experiences:- What is the lived experience of older people with social care needs and multiple long-term conditions?

    lived experience of older people with social care needs and multiple long-term conditions? Any explanatory notes(if applicable) Why this...

  9. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

  10. Developing and updating local formularies (MPG1)

    This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

  11. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  12. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

  13. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

  14. Audit:- What is the clinical and cost effectiveness of collecting long-term outcomes in a national trauma audit system?

    Audit:- What is the clinical and cost effectiveness of collecting long-term outcomes in a national trauma audit system? Any explanatory...

  15. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  16. Excess winter deaths and illness and the health risks associated with cold homes (NG6)

    This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.

  17. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

  18. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  19. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  20. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

  21. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  22. Intermediate care including reablement (QS173)

    This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.

  23. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  24. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes. Any explanatory notes(if...

  25. Radiofrequency denervation:- What is the clinical and cost effectiveness of radiofrequency denervation for chronic low back pain in the long term?

    effectiveness of radiofrequency denervation for chronic low back pain in the long term? Any explanatory notes(if applicable) Why this is...

  26. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  27. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  28. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

  29. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.

  30. Renal replacement therapy services for adults (QS72)

    This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.

  31. Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the chest wall?

    NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the...

  32. Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

    This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

  33. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  34. Medicines optimisation (QS120)

    This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.

  35. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

  36. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  37. Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

    Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.

  38. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  39. Depression in children and young people: identification and management (NG134)

    This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.

  40. What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin therapy?

    Recommendation ID CG71/2 Question What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH

  41. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  42. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  43. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

  44. Glaucoma: diagnosis and management (NG81)

    This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing.

  45. Subsequent health assessment:- When should subsequent health assessments be carried out in prison for people serving long-term sentences?

    subsequent health assessments be carried out in prison for people serving long-term sentences? Any explanatory notes(if applicable) Why...

  46. Looked-after children and young people (NG205)

    This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.